Trial Acronym | EASI-SWITCH |
Clinical Area | Cancer |
Description | Interventional study comparing whether early switch to oral antibiotics 12-24 hours after intravenous antibiotic treatment commences in patients with low risk of neutropenic sepsis is non-inferior to standard care. This is a randomised, controlled, non-inferiority trial with allocation concealment. Both arms of the trial will be conducted in parallel. |
Status | ANALYSIS AND REPORTING |
Recruitment duration | 1st January 2020 |
Target Recruitment | 628 |
Recruitment to date | 129 |
Trial Design | A multi-centre, interventional, randomised, controlled, non-inferiority trial with allocation concealment. |
Study Aim | To establish the clinical and cost-effectiveness of early switch to oral antibiotics, 12-24 hours after intravenous antibiotic treatment commences in low risk cancer patients with neutropenic sepsis. |
Chief Investigator | Dr Victoria Coyle & Dr Ronan McMullan |
Sponsor | Belfast Health and Social Care Trust |
Funder | National Institute for Health Research |